ClinicalTrials.gg
CompletedNCT00165672Updated Oct 5, 2011Results posted

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

A Phase 3 interventional study of RABEPRAZOLE SODIUM and RABEPRAZOLE SODIUM in Non-erosive Gastroesophageal Reflux Disease, sponsored by Eisai Inc.. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-10-05.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
34th of 39
26 · median 100
Started
2005
with 6 others
Phase 3
16 of 40
none open now
Registered
3rd of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2005, is one of 16 in phase 3, and was the 3rd registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).

03

Conditions studied

  • Non-erosive Gastroesophageal Reflux Disease

Keywords

  • 24-hour esophageal pH monitoring
  • non-erosive gastroesophageal reflux disease
  • NERD
  • proton pump inhibitor
  • rabeprazole
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The patients to be included will be outpatients who meet all of the following criteria. No specific gender is asked.

\<For the observation period>

  1. Patients who have "heartburn" 2 days a week or more during consecutive 3 weeks* prior to pre-observation screening. *If a day of screening and a day of starting observation (date of registration) are different, heartburn must continuously be present during the in-between period.
  2. Patients who meet both 1) and 2) below;
  1. The symptom is a burning sensation arising from the stomach or the lower chest.
  1. The symptom tends to appear frequently or is aggravated after eating, when bending a body forward, and/or when pressing on the abdomen.
  1. Patients categorized in "grade M" (discoloring type: minimal change) according to the Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.
  1. Patients who are 20 years old or older at the time of obtaining consent.
  1. Patients who are informed of the objective and details of this study and give written consent for study entry.

\<For the treatment period>

  1. Patients who have "heartburn" 2 days a week or more during 7 days until the treatment period (during the observation period).
  2. Patients with "heartburn diary" that is completely filled out during 7 days until the treatment period (during the observation period). If the observation period is 8 days or longer, those with a heartburn diary of which entries are fulfilled 80% or more during the observation period.
  3. Patients with 80% or better drug compliance for antacids during the observation period.
  4. Patients whose percentage of time showing pH\<4.0 (% time pH\<4.0) is not 0%* during the 24-hour esophageal pH monitoring at the end of observation period (at the beginning of treatment period). *If parameters calculated from analytical program show 0.0% after round-off, this patient cannot be entered into the treatment period.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Patients who cannot keep adequate entries of a heartburn diary by themselves.
  2. Patients who strongly complain "feeling of heavy stomach" and/or "abdominal bloating."
  3. Patients who have a complication or history of psychiatric or psychosomatic disease (e.g., manic-depressive psychosis, obsessive-compulsive neurosis, or others) or those who are on an antidepressant or anti-anxiety agent (accepted if only for a hypnotic treatment).
  4. Patients who have undergone Helicobacter pylori eradication therapy, and less than 6 months* have elapsed from the end of H. pylori eradication therapy to the beginning of the observation period. *: The same day 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  5. Patients with open gastric or duodenal ulcer.
  6. Patients with acute gastritis.
  7. Patients with a history of any surgical intervention that affect peptic secretion (e.g., upper gastrointestinal tract resection and/or vagotomy).
  8. Patients with Barrett's esophagus, esophageal stenosis, or pyloric stenosis.
  9. Patients with scleroderma.
  10. Patients with a history or complication of angina pectoris.
  11. Patients who work at night (working for a night-shift).
  12. Patients who received proton pump inhibitors (PPIs) within 3 weeks prior to pre-observation screening.
  13. Patients who need non steroidal anti-inflammatory drugs (NSAIDs) (except topical preparations), (except topical preparations), and/or aspirin treatment every day.
  14. Patients receiving dialysis therapy.
  15. Patients with a serious complication such as cardiovascular disease (myocardial infarction, etc.), hematological disorder (e.g, aplastic anemia), renal disease (e.g., acute or chronic renal failure), hepatic disease (e.g., cirrhosis), or malignant tumor.
  16. Patients with known to antacids or PPIs.
  17. Patients who are pregnant or those with , or those who wish to become pregnant or are lactating during the study period.
  18. Patients receiving another drug or those who received another investigational drug within 6 months prior to pre-observation screening* *: Registration is allowed on the same day of 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  19. Patients who are judged to be ineligible for the study entry by the investigator or subinvestigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    Drug: RABEPRAZOLE SODIUM

  • Experimental
    2

    Drug: RABEPRAZOLE SODIUM

Interventions

06

What researchers measure

Primary outcomes

  1. The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).

    Mean and standard deviation of percent time pH\<4.0 on 24 hour esophageal pH monitoring.

    Time frame: Baseline and 4 weeks

07

Results

Posted Oct 5, 2011

Participant flow

This study was recruited at 13 centers in Japan during the period of May-2005 to Oct-2005.

Participant flow — Overall Study
MilestoneE3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mg
Started1313
Completed1312
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryThe Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).

Mean and standard deviation of percent time pH\<4.0 on 24 hour esophageal pH monitoring.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Percent Time
The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).
Percent TimeE3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mg
Baseline6.72 ± 5.307.03 ± 4.76
4 weeks1.38 ± 0.790.87 ± 1.22

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E3810 Pariet (Rabeprazole Sodium) 5 mg—0/13 (0%)6/13 (46.2%)
E3810 Pariet (Rabeprazole Sodium) 10 mg—0/13 (0%)10/13 (76.9%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventE3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mg
DiarrhoeaGastrointestinal disorders3/131/13
HeadacheNervous system disorders1/132/13
Gastrooesophageal reflux diseaseGastrointestinal disorders0/132/13
NauseaGastrointestinal disorders2/130/13
CellulitisInfections and infestations0/131/13
NasopharyngitisInfections and infestations0/131/13
Tympanic membrane perforationEar and labyrinth disorders0/131/13
CoughRespiratory, thoracic and mediastinal disorders1/131/13
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/131/13
Abdominal distensionGastrointestinal disorders1/131/13

Baseline characteristics

Age Continuous
Age Continuous(years)E3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mgTotal
Mean40.6 ± 20.042.7 ± 15.841.6 ± 17.5
Sex: Female, Male
Sex: Female, Male(Participants)E3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mgTotal
Female347
Male6511
Race (NIH/OMB)
Race (NIH/OMB)(Participants)E3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mgTotal
Asian9918
Region of Enrollment
Region of Enrollment(participants)E3810 Pariet (Rabeprazole Sodium) 5 mgE3810 Pariet (Rabeprazole Sodium) 10 mgTotal
Japan9918
08

Study locations

13 sites
  • Nagoya, Aichi-Prefecture 467-0001, Japan
  • Fukuoka, Fukuoka-Prefecture 810-0001, Japan
  • Fukuoka, Fukuoka-Prefecture 811-0213, Japan
  • Yukuhashi, Fukuoka-Prefecture 824-0026, Japan
  • Hiroshima, Hiroshima-Prefecture 734-0037, Japan
  • Osaka, Osaka-Prefecture 530-0012, Japan
  • Osaka, Osaka-Prefecture 545-0051, Japan
  • Saga, Saga-Prefecture 849-0937, Japan
  • Otsu, Shiga-Prefecture 520-2121, Japan
  • Izumo, Shimane-Prefecture 693-0021, Japan
  • Bunkyo-ku, Tokyo 113-0022, Japan
  • Shinjuku-ku, Tokyo 162-0052, Japan
  • Ube, Yamaguchi-Prefecture 755-0046, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 14, 2005
Start
May 2005
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Results first posted
Oct 5, 2011
Last update
Oct 5, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00165672
Lead sponsor
Eisai Inc.
Collaborators
Eisai Limited
First posted
Sep 14, 2005
Start date
May 2005
Primary completion
Oct 2005
Completion
Oct 2005
Results posted
Oct 5, 2011
Last update
Oct 5, 2011

Study contacts

Nobuyuki Sugisaki
study director · Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion